EUVIMEDSkopri EUVIMED
Open access · CC BY-NC 4.0

Neurofilament light chain as in vitro and clinical biomarker of vincristine‐induced peripheral neuropathy

Peter Erik Lotko Pontoppidan iD, Christian Bach Vase, Christina Mortensen, Liv Andres-Jensen, Dorte Aalund Olsen, Jonna Skov Madsen, Kjeld Schmiegelow, Rene Mathiasen, Tore Bjerregaard Stage iD

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70599 ↗

At a glance

Journal article in British Journal of Clinical Pharmacology, 2026. Written by Peter Erik Lotko Pontoppidan and 8 co-authors. Institution: Department of Pediatrics and Adolescent Medicine, Clinic of Pediatric Oncology and Hematology Rigshospitalet, University of Copenhagen, Denmark. Major MEDLINE topics: Vincristine, Peripheral Nervous System Diseases, Neurofilament Proteins, Antineoplastic Agents, Phytogenic. Cited 2 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Danish Childhood Cancer Foundation, Danish Cancer Society, Børnecancerfonden.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Aims

Vincristine‐induced peripheral neuropathy (VIPN) is a common side effect in children and adolescents treated with vincristine. Assessing VIPN, especially in young children, is challenging due to a lack of sensitive tools. This limits our understanding of the nature and risk factors of VIPN. This study aimed to investigate neurofilament light chain (NfL) as a biomarker of nerve damage in vitro and in vivo .

Methods

Induced pluripotent stem cells (iPSC) were differentiated into sensory neurons (SN) and exposed to incremental concentrations of vincristine. Cells were fixed and immunolabelled to showcase structural damage and media were collected for assessment of NfL. Furthermore, we performed a prospective, self‐controlled clinical trial in 21 children with acute lymphoblastic leukaemia (ALL) during their 36‐day weekly vincristine induction and assessed VIPN symptoms using Common Terminology Criteria for Adverse Events (CTCAE). Blood was drawn before or shortly after initiating treatment and every week following initiation of treatment to assess NfL in serum (sNfL).

Results

In vitro studies using iPSC‐SN showed that vincristine exposure caused substantial structural damage and a dose‐dependent increase in NfL release to cell medium. In this pilot study, median sNfL increased from 8.9 pg/mL pre‐treatment to 158.5 pg/mL by day 36, coinciding with worsening sensory and motor symptoms. However, in this pilot study, no statistically significant correlation between sNfL levels and CTCAE was found.

Conclusion

Vincristine causes concentration‐dependent NfL release in vitro , and sNfL levels increase during vincristine treatment. Further studies are needed to investigate sNfL's potential as a biomarker of VIPN in children with ALL.

Subjects

MeSH terms (MEDLINE)

VincristinePeripheral Nervous System DiseasesNeurofilament ProteinsAntineoplastic Agents, PhytogenicHumansBiomarkersMaleFemalePrecursor Cell Lymphoblastic Leukemia-LymphomaChildProspective StudiesInduced Pluripotent Stem CellsDose-Response Relationship, DrugAdolescentChild, PreschoolSensory Receptor Cells

Author keywords

Neurofilament light chainchildhood acute lymphoblastic leukaemiaperipheral neuropathyvincristine

Substances

VincristineBiomarkersNeurofilament ProteinsAntineoplastic Agents, Phytogenicneurofilament protein L

Authors and institutions

  • Department of Pediatrics and Adolescent Medicine, Clinic of Pediatric Oncology and Hematology Rigshospitalet, University of Copenhagen, Denmark.
  • Pediatric Oncology Research Laboratory, Department of Pediatrics and Adolescent Medicine, Rigshospitalet, University of Copenhagen, Denmark.
  • Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health University of Southern Denmark, University of Southern Denmark, Odense, Denmark.
  • Department of Biochemistry and Immunology, Lillebaelt University Hospital Vejle, Odense, Denmark.
  • Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.

ORCID profiles: Peter Erik Lotko Pontoppidan, Tore Bjerregaard Stage

Funding

  • Danish Childhood Cancer Foundation
  • Danish Cancer Society
  • Børnecancerfonden
  • Kræftens Bekæmpelse

Cite

APA

Pontoppidan, P. E. L., Vase, C. B., Mortensen, C., Andres-Jensen, L., Olsen, D. A., Madsen, J. S., Schmiegelow, K., Mathiasen, R., & Stage, T. B. (2026). Neurofilament light chain as in vitro and clinical biomarker of vincristine‐induced peripheral neuropathy. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70599

Vancouver

Pontoppidan PEL, Vase CB, Mortensen C, Andres-Jensen L, Olsen DA, Madsen JS, et al. Neurofilament light chain as in vitro and clinical biomarker of vincristine‐induced peripheral neuropathy. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70599

BibTeX
@article{Pontoppidan2026,
  author = {Pontoppidan, Peter Erik Lotko and Vase, Christian Bach and Mortensen, Christina and Andres-Jensen, Liv and Olsen, Dorte Aalund and Madsen, Jonna Skov and Schmiegelow, Kjeld and Mathiasen, Rene and Stage, Tore Bjerregaard},
  title = {Neurofilament light chain as in vitro and clinical biomarker of vincristine‐induced peripheral neuropathy},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70599}
}
Start for free →